Health
Dapagliflozin Misses Early Mark in COVID-19, but Kosiborod Sees Reasons for More Study – AJMC.com Managed Markets Network
The Dapagliflozin in Respiratory Failure in Patients With COVID-19 trial is the first phase 3 study to examine whether this SGLT2 inhibitor, which has proven effective…
A study that misses its mark would not typically generate this much interest, especially after trial sponsor AstraZeneca announced last month that results fell short of statistical significance. But with SGTL2 inhibitors gaining indications in heart failure and CKD, along with their original T2D approvalsconditions that put patients in danger when they get COVID-19many suspect this weekends results will not be the last word.
Since Kosiborod is one of the worlds leading experts on SGLT2 inhibitors,…
-
Noosa News19 hours agoBrisbane’s original 1979 electric trains take one last journey
-
General24 hours agoNRL live updates: Canberra Raiders vs St George Illawarra Dragons, North Queensland Cowboys vs Melbourne Storm
-
General24 hours agoWA road toll hits decade high as five people killed in 24 hours
-
General18 hours agoParis opens River Seine for public swimming for first time since 1923